Current partner codePEPTIDESDE
PeptideStat
Menu

Vendors

Compare pricesVendor directoryVendor reviewsDiscount codesLab tests & COAs

Research

ResearchDatabaseClinical trials

Tools

All calculatorsReconstitutionAccumulationUnit converterPeptide chemistry
Evidence dashboardStudies since 2019Updated Jul 31, 2026

SemaglutideClinical Trials.

A source-linked view of every Semaglutide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.

Total trials
75
Recruiting
33
Completed
12
Terminated
0
Results posted
1
Average enrollment
499
Countries
46
Highest phase
Phase 4

Largest indexed study

120,000 participants · NCT07619495 →

Developer / research origin

Novo Nordisk

Evidence summary

Activity is not efficacy.

Semaglutide appears in 75 indexed studies: 33 recruiting, 12 completed and 1 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Semaglutide is safe or effective.

Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.

Development history

Trial timeline.

Evidence timeline

2019—2027

201920212021202220222022202220222023202320232024202420242024202420242025

Velocity

Semaglutide studies by start year

Study start year · indexed snapshot

3325178020192019: 1 trials2020: 1 trials20212021: 3 trials2022: 5 trials20232023: 5 trials2024: 9 trials20252025: 16 trials2026: 33 trials20272027: 2 trials

Development

Trials by phase

Early Phase 11
Phase 17
Phase 218
Phase 315
Phase 48

Current studies

Recruiting or active

Completed studies

Finished records

Stopped studies

Withdrawn or terminated

Showing 6 of 61 studies
Showing 6 of 12 studies

Full study index

Search Semaglutide trials.

Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.

75 matching studies

Latest publications

Follow the paper trail.

PMID 41168808 ↗Freet CS, Shuler K, Kawasaki S, Weintraub E, Greenblatt A, Kladney M, Nunes E, Foster KL, Kong L, Raja-Khan N, Cleveland HH, Grigson PS, Bunce SC, Brick TR, Nyland JE. Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with OUD: a randomized, double-blind, placebo-controlled clinical trial protocol. Addict Sci Clin Pract. 2025 Oct 30;20(1):89. doi: 10.1186/s13722-025-00618-2.Linked from NCT06548490PMID 40502777 ↗Freet CS, Shuler K, Kawasaki S, Weintraub E, Greenblatt A, Kladney M, Nunes E, Foster KL, Kong L, Raja-Khan N, Cleveland HH, Grigson PS, Bunce SC, Brick TR, Nyland JE. Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol. Res Sq [Preprint]. 2025 May 26:rs.3.rs-6666196. doi: 10.21203/rs.3.rs-6666196/v1.Linked from NCT06548490PMID 32520773 ↗Smith SM, Dworkin RH, Turk DC, McDermott MP, Eccleston C, Farrar JT, Rowbotham MC, Bhagwagar Z, Burke LB, Cowan P, Ellenberg SS, Evans SR, Freeman RL, Garrison LP, Iyengar S, Jadad A, Jensen MP, Junor R, Kamp C, Katz NP, Kesslak JP, Kopecky EA, Lissin D, Markman JD, Mease PJ, O'Connor AB, Patel KV, Raja SN, Sampaio C, Schoenfeld D, Singh J, Steigerwald I, Strand V, Tive LA, Tobias J, Wasan AD, Wilson HD. Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. Pain. 2020 Nov;161(11):2446-2461. doi: 10.1097/j.pain.0000000000001952.Linked from NCT07731256PMID 34051018 ↗van Lennep JHPA, Trossel F, Perez RSGM, Otten RHJ, van Middendorp H, Evers AWM, Szadek KM. Placebo effects in low back pain: A systematic review and meta-analysis of the literature. Eur J Pain. 2021 Oct;25(9):1876-1897. doi: 10.1002/ejp.1811. Epub 2021 Jun 21.Linked from NCT07731256PMID 37385275 ↗Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26.Linked from NCT07731256PMID 28192789 ↗Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of Physicians; Denberg TD, Barry MJ, Boyd C, Chow RD, Fitterman N, Harris RP, Humphrey LL, Vijan S. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 4;166(7):514-530. doi: 10.7326/M16-2367. Epub 2017 Feb 14.Linked from NCT07731256PMID 35507483 ↗Chiarotto A, Koes BW. Nonspecific Low Back Pain. N Engl J Med. 2022 May 5;386(18):1732-1740. doi: 10.1056/NEJMcp2032396. No abstract available.Linked from NCT07731256PMID 8080219 ↗Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994 Mar;23(2):129-38.Linked from NCT07731256

Related pages

Keep researching Semaglutide.

Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.

DatabaseSemaglutide database page →Research guideRead the Semaglutide guide →Lab reportsSearch the COA ledger →Source registrySearch ClinicalTrials.gov ↗